Adult primary glomerular diseases due to podocytopathies: a single center experience on patient characteristics, treatment and outcomes
Öz
Purpose: This study aims to evaluate the demographic, clinical, and pathologic characteristics and response to immunosuppressive therapy, particularly corticosteroids, in adult patients with primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), which are classified as podocytopathies.
Materials and Methods: Between January 1998 and December 2014, this study included 44 patients (27 with primary FSGS and 17 with MCD) aged older than 18 years with a histopathologic diagnosis, symptoms of nephrotic syndrome, and a minimum follow-up of six months. Patients were divided into two groups according to the treatment they received and three groups according to their response to treatment. Patients diagnosed with primary FSGS and MCD were evaluated based on clinical, demographic, and laboratory findings, as well as response to treatment, and a comparison was conducted between the two groups.
Results: 59.1% of the patients were male with a mean age of 44.8±17.7 years. At the time of diagnosis, there were no statistically significant differences in clinical and demographic characteristics between MCD and primary FSGS patients. However, in patients with MCD, the mean creatinine clearance (118.0±46.7 ml/min) was higher and the rate of microscopic hematuria (11.8%) was lower at the time of diagnosis. There was an increased need for alternative immunosuppressive treatments besides corticosteroids in patients with primary FSGS to achieve partial or complete remission. At both the third and sixth-month follow-ups, MCD patients achieved a higher rate of complete remission (proteinuria <0.3 g/day) than FSGS patients.
Conclusion: Compared to MCD, primary FSGS is more likely to progress, requires more immunosuppressive therapy beyond corticosteroids to achieve partial or complete remission, and has a lower treatment response rate.
Anahtar Kelimeler
Podocytopathy, Primary focal segmental glomerulosclerosis, minimal change disease, proteinuria, prognosis
Kaynakça
- Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387:2036-48.
- Ahn W, Bomback AS. Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults: core curriculum 2020. Am J Kidney Dis. 2020;75:955-64.
- Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol. 2007;29:415-26.
- Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12:768-76.
- Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant. 1998;13:10-5.
- Bonegio RG, Salant DJ, Fervenza FC. Mechanisms of immune injury of the glomerulus. https://www.uptodate.com/contents/3068 (accessed Sept 2023).
- Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276.
- Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445-53.
- Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol. 2013;24:702-11.
- Meyrier A, Radhakrishnan J, Fervenza FC. Minimal change disease: treatment in adults. https://www.uptodate.com/contents/minimal-change-disease-treatment-in-adults (accessed Sept 2023).
